Table 3 Characteristics of oligometastatic primary lung cancer (n = 24) receiving Tomotherapy
From: Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy
Case | Sex | Age | Stage | Pathological diagnosis | Dose (cGy x fx) | Intrathoracic Targets | Major Systemic Therapy | Status | Survival time (mo) |
|---|---|---|---|---|---|---|---|---|---|
1 | F | 53 | T4N2M1,IV | NSCLC | 450 × 10 | 5 | TKI | D | 51.2 |
2 | M | 58 | M1, IV | AD | 450 × 10 | 2 | TKI | D | 40.6 |
3 | M | 31 | M1, IV | AD | 450 × 10 | 3 | CT (Alimta) | A | 39.0 |
4 | M | 59 | M1, IV | AD | 450 × 11 | 3 | CT (Navelbine) | D | 6.0 |
5 | M | 43 | M1, IV | AD | 450 × 10 | 1 | TKI | D | 13.4 |
6 | M | 79 | T1NxM1, IV | AD | 500 × 9 | 2 | CT(Endoxan + UFUR) | D | 8.2 |
7 | F | 49 | T1N0M1, IV | AD | 500 × 9 | 1 | CT (Alimta) | A | 29.7 |
8 | F | 80 | M1, IV | AD | 450 × 10 | 1 | TKI | D | 4.6 |
9 | M | 69 | M1, IV | AD | 450 × 12 | 5 | CT (Navelbine) | D | 5.1 |
10 | M | 79 | T2N0M1,IV | NSCLC | 450 × 16 | 1 | CT (Navelbine) | D | 6.7 |
11 | M | 64 | T2N0M1, IV | AD | 550 × 10 | 1 | TKI | D | 11.2 |
12 | M | 71 | rT4, IV | SqCC | 500 × 12 | 1 | CT (Navelbine) | D | 12.3 |
13 | F | 74 | T4N2M1,IV | AD | 450 × 10 | 1 | TKI | A | 26.2 |
14 | M | 73 | rT1a,IV | AD | 450 × 10 | 1 | TKI | A | 24.3 |
15 | M | 67 | rT3,IV | NSCLC | 500 × 10 | 1 | CT(Endoxan + UFUR) | A | 14.8 |
16 | F | 70 | M1,IV | AD | 500 × 9 | 2 | TKI | A | 20.0 |
17 | F | 45 | M1,IV | AD | 550 × 10 | 1 | TKI | D | 34.7 |
18 | M | 50 | T2aN0M1,IV | AD | 500 × 10 | 1 | TKI | A | 25.8 |
19 | M | 78 | M1,IV | SqCC | 450 × 10 | 1 | CT (Navelbine) | D | 4.2 |
20 | M | 47 | rN1,IV | AD | 450 × 10 | 1 | TKI | A | 41.6 |
21 | M | 68 | T1N2M1,IV | AD | 450 × 10 | 5 | TKI | D | 32.1 |
22 | M | 79 | M1,IV | AD | 450 × 10 | 3 | CT (Navelbine) | D | 3.0 |
23 | F | 79 | rT3, IV | SqCC | 450 × 12 | 2 | CT (Navelbine) | A | 60.7 |
24 | F | 58 | M1b,IV | AD | 450 × 10 | 1 | TKI | A | 10.1 |